

Bayer HealthCare Pharmaceuticals



Dear Valued Customer,

Bayer HealthCare Pharmaceuticals is pleased to announce the return of Ultravist® 370 mg/ml to the U.S. market. On behalf of our company, we thank you for your support during the last year, and apologize for any inconvenience you may have experienced from the temporary unavailability of this product.

As you may know, on July 31, 2006 Bayer HealthCare Pharmaceuticals voluntarily recalled existing stocks of Ultravist 370 and suspended further production, following reports of spontaneous crystallization. The voluntary recall was a precautionary measure and was not based on or triggered by an adverse reaction report.

Since then, a comprehensive corrective action plan was developed to minimize the potential for spontaneous crystallization, and these measures have been implemented prior to resuming production of Ultravist 370.

As always, Bayer HealthCare Pharmaceuticals continues to adhere to the highest quality standards in the interest of patient safety. Effective August 1, 2007, Ultravist 370 will once again be available. The well-documented safety profile of Ultravist remains unchanged. We are also increasing our efforts to educate our customers on the proper handling of X-ray contrast media to underscore the importance of diligent product handling, including final visual inspection, prior to administration.

Once again, we appreciate and thank you for your understanding and continued support. Please contact your Bayer HealthCare Pharmaceuticals representative if you should have any questions regarding Ultravist 370.

With best regards,

Stephen Dougherty
Deputy Director, Ultravist Brand Management
Bayer HealthCare Pharmaceuticals Inc.

Ultravist® (iopromide) injection: All nonionic, iodinated contrast media currently available inhibit blood coagulation in vitro less than ionic contrast media. Clotting has been reported when blood remains in contact with syringes containing nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary to minimize thromboembolic events. As with all iodinated contrast agents, serious or fatal reactions have been associated with their use. Ultravist injection is not indicated for intrathecal use.

Bayer HealthCare
Pharmaceuticals Inc.
Diagnostic Imaging
6 West Belt
Wayne, NJ 07470-6806

Phone: 973 305-5000
Fax: 973-305-5490
pharma.bayer.com